一例重症肌无力患者LRP4/Agrin抗体的致病性特征
本研究从一例携带抗LRP4/Agrin抗体的重症肌无力患者中纯化免疫球蛋白并被动转移至小鼠,评估其致病性及机制。结果显示小鼠出现体重下降、肌无力、复合肌肉动作电位减低、神经肌肉接头结构破坏等表现;患者Ig可抑制agrin诱发的MuSK激活及AChR聚集,并识别LRP4的β3结构域与agrin的C末端,减少agrin增强的LRP4-MuSK相互作用。结论提示该患者抗LRP4/Agrin抗体具有致病性,通过干扰agrin依赖的LRP4-MuSK相互作用损害神经肌肉接头。
要点
- 患者抗LRP4/Agrin抗体被动转移可致小鼠出现肌无力及神经肌肉接头功能障碍。
- 抗体通过阻断agrin增强的LRP4-MuSK相互作用抑制AChR聚集。
- 抗体识别LRP4的β3结构域和agrin的C末端。
核心结论
- 该重症肌无力患者体内的抗LRP4/Agrin抗体具有致病性,通过干扰agrin依赖的LRP4-MuSK相互作用损害神经肌肉接头。
研究设计与样本
- 从一例携带抗LRP4/Agrin抗体的重症肌无力患者中纯化免疫球蛋白并转移至小鼠,评估体重、肌力、神经肌肉接头功能与结构,并体外研究抗体对agrin诱发的MuSK激活及AChR聚集的影响,鉴定抗体表位。
主要发现
- 患者Ig注射小鼠出现体重下降和肌无力等MG症状,并检测到CMAP减低、单收缩与强直收缩力下降、神经肌肉传递受损以及神经肌肉接头碎片化和扭曲。
- 患者Ig抑制agrin诱发的MuSK激活和AChR聚集。
- 患者Ig识别LRP4的β3结构域和agrin的C末端,并减少agrin增强的LRP4-MuSK相互作用。
临床怎么用
- 对于重症肌无力患者,若检出抗LRP4/Agrin抗体,应认识到其可能具有致病性,并关注神经肌肉接头传递障碍的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: To determine whether human anti-LRP4/agrin antibodies are pathogenic in mice and to investigate underpinning pathogenic mechanisms. METHODS: Immunoglobulin (Ig) was purified from a patient with myasthenia gravis (MG) with anti-LRP4/agrin antibodies and transferred to mice. Mice were characterized for body weight, muscle strength, twitch and tetanic force, neuromuscular junction (NMJ) functions including compound muscle action potential (CMAP) and endplate potentials, and NMJ structure. Effects of the antibodies on agrin-elicited muscle-specific tyrosine kinase (MuSK) activation and AChR clustering were studied and the epitopes of these antibodies were identified. RESULTS: Patient Ig-injected mice had MG symptoms, including weight loss and muscle weakness. Decreased CMAPs, reduced twitch and tetanus force, compromised neuromuscular transmission, and NMJ fragmentation and distortion were detected in patient Ig-injected mice. Patient Ig inhibited agrin-elicited MuSK activation and AChR clustering. The patient Ig recognized the β3 domain of LRP4 and the C-terminus of agrin and reduced agrin-enhanced LRP4-MuSK interaction. DISCUSSION: Anti-LRP4/agrin antibodies in the patient with MG is pathogenic. It impairs the NMJ by interrupting agrin-dependent LRP4-MuSK interaction.
引用
- Yu Z, Zhang M, Jing H, et al. Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis. Neurology. 2021. PMID: 34233932. doi:10.1212/WNL.0000000000012463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。